Sensyne Health PLC (LON:SENS) said it has extended its relationship with Microsoft to become a strategic partner of the US software giant with the pair working together on the former’s clinical AI and health cloud technologies.
Practically, the enhanced tie-up is set to deliver the latest 'cloud-first' healthcare systems and cutting-edge predictive machine learning algorithms.
With Microsoft’s help, Sensyne said it aims to create “highly configurable” healthcare technologies that are globally deployable and able to meet local, clinical and regulatory needs.
To do this it will have early access to the international tech group’s tools, enabling it to build new products with state-of-the-art features to enhance usability and cyber-security.
Commercially, the alliance will help broaden Sensyne’s sales channels.
The pair will ‘co-sell’ two Sensyne products: SEND, a remote monitoring system for vital signs in hospitals; and GDm-Health, a prescribed digital therapeutic for the management of diabetes during pregnancy at home.
In a statement, Sensyne chief executive Lord Drayson said: "This strategic partnership with Microsoft will further enhance Sensyne's ability to advance and scale the benefits that advanced clinical AI can bring to improve patient outcomes and accelerate the development of new medicines through its research partnerships with NHS Trusts."